Maze Therapeutics (MAZE) Change in Accured Expenses (2024 - 2026)

Maze Therapeutics has reported Change in Accured Expenses for 3 years, with the latest figure at -$4.1 million in Q1 2026.

• Quarterly Change in Accured Expenses fell 282.5% year-over-year to -$4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $479000.0 (down 83.34% YoY) and the FY2025 annual result came in at $3.5 million, down 8.54% from the prior year.
• Change in Accured Expenses slipped to -$4.1 million in Q1 2026 per MAZE's latest filing, from $2.0 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $3.8 million in Q2 2024 and troughed at -$4.1 million in Q1 2026.
• A 3-year average of $358111.1 and a median of $106000.0 in 2025 frame the typical range for Change in Accured Expenses.
• The widest YoY moves for Change in Accured Expenses: up 245.31% in 2025, down 711.45% in 2025.
• Over 3 years, Change in Accured Expenses stood at $1.8 million in 2024, then gained by 6.51% to $2.0 million in 2025, then tumbled by 307.13% to -$4.1 million in 2026.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$4.1 million, $2.0 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.